| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 09/12/2008 | WO2008108322A2 Composition and method for protecting mitochondria |
| 09/12/2008 | WO2008108286A1 Medicinal composition for transdermal absorption, medicinal composition storing unit and transdermal absorption preparation using the same |
| 09/12/2008 | WO2008107909A1 Pharmaceutical compositions comprising trigonelline and 4-hydroxyisoleucine and a process thereof |
| 09/12/2008 | WO2008107862A2 Use of ngf for the preparation of medicaments for the cure of reactive gliosis |
| 09/12/2008 | WO2008107544A1 Derivatives of n-(heteroaryl)-1-heteroaryl-1h-indol-2-carboxamids, preparation thereof and therapeutic use thereof |
| 09/12/2008 | WO2008107481A1 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
| 09/12/2008 | WO2008107480A1 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive mglur2 -receptor modulators |
| 09/12/2008 | WO2008107479A1 3-cyano-4-(4-phenyl-piperidin-1-yl)-pyridin-2-one derivatives |
| 09/12/2008 | WO2008107455A1 Indazoles used to treat estrogen receptor beta mediated disorders |
| 09/12/2008 | WO2008107418A1 Fused pyrimidinone compounds as mglur ligands |
| 09/12/2008 | WO2008107399A1 Substituted oxindole compounds |
| 09/12/2008 | WO2008107334A2 Process for the synthesis of glyt-1 inhibitors |
| 09/12/2008 | WO2008106896A1 Transgenic rodents having ngf beta gene mutants and its preparation methods, the preparation methods of the corresponding mutant proteins and the resulting mutant proteins |
| 09/12/2008 | WO2008106863A1 The use of iridoids in the manufacture of the medicine for promoting nerve cell proliferation and differentiation |
| 09/12/2008 | WO2008089453A3 Inhibitors of d-amino acid oxidase |
| 09/12/2008 | WO2008049073A3 Compositions for the treatment of inflammation in the brain and other tissues |
| 09/12/2008 | WO2007137168A3 Bridged aryl piperazines derivatives useful for the treatment of cns, gi-urinary and reproductive disorders |
| 09/12/2008 | WO2007120912A3 Compositions and methods for suppression of amyloid plaque formation associated with neurodegenerative disorders. |
| 09/12/2008 | WO2007113309A3 Compounds which inhibit the glycine transporter and uses thereof |
| 09/12/2008 | WO2007073176A3 Composition comprising a polyunsaturated fatty acid for improving membrane composition |
| 09/12/2008 | WO2006116148A3 (7-arlysubstituted 2, 3-dihydr0-1-benz0furan-2-yl) alkylamines in the treatment' of substance abuse |
| 09/12/2008 | WO2006065968A8 The uses of estrogen beta agonists to treat cognitive diseases |
| 09/12/2008 | CA2707757A1 Process for the preparation of quaternary n-alkyl morphinan alkaloid salts |
| 09/12/2008 | CA2680324A1 Methods for treating cognitive disorders using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds |
| 09/12/2008 | CA2680125A1 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive mglur2-receptor modulators |
| 09/12/2008 | CA2680120A1 3-cyano-4-(4-phenyl-piperidin-1-yl)-pyridin-2-one derivatives |
| 09/12/2008 | CA2680109A1 Indazoles used to treat estrogen receptor beta mediated disorders |
| 09/12/2008 | CA2680104A1 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
| 09/12/2008 | CA2679917A1 Compositions and treatments for seizure-related disorders |
| 09/12/2008 | CA2679807A1 Piperidine derivatives and methods of use thereof |
| 09/12/2008 | CA2679735A1 Tetrahydroisoquinoline compounds as modulators of the histamine h3 receptor |
| 09/12/2008 | CA2679670A1 Indole and benzothiophene compounds as modulators of the histamine h3 receptor |
| 09/12/2008 | CA2679316A1 Medicinal composition for transdermal absorption, medicinal composition storing unit and transdermal absorption preparation using the same |
| 09/12/2008 | CA2679206A1 Pharmaceutical compositions comprising trigonelline and 4-hydroxyisoleucine and a process thereof |
| 09/12/2008 | CA2678630A1 Synthesis of glyt-1 inhibitors |
| 09/12/2008 | CA2678463A1 Fused pyrimidinone compounds as mglur ligands |
| 09/12/2008 | CA2678424A1 Percutaneous administration device of bisoprolol |
| 09/12/2008 | CA2678100A1 Bicyclic oxomorpholine derivative |
| 09/11/2008 | US20080221199 Method for improving memory in mammals |
| 09/11/2008 | US20080221193 3-amino chromane derivatives |
| 09/11/2008 | US20080221188 (S)(-)-2-(7-chloro-6-fluoro-1H-benzimidazol-1-yl)-N-{1-[4-(1-cyano-1-methylethyl)phenyl]ethyl}acetamide; treatment of pain; vanilloid receptor inhibitor; Antagonists maintain analgesic properties, but avoid pungency and neurotoxicity side effects of agonists |
| 09/11/2008 | US20080221186 4-(substituted cycloalkylmethyl) Imidazole-2-Thiones, 4-(substituted cycloalkenylmethyl) Imidazole-2-Thiones, 4-(substituted cycloalkylmethyl) Imidazol-2-Ones and 4-(substituted cycloalkenylmethyl) Imidazole-2-Ones and related compounds |
| 09/11/2008 | US20080221185 Psychoses, dementia or attention deficit disorder; 2-[3-(4-chlorophenyl)-2-oxo-1,4-diazaspiro[4.5]dec-3-en-1-yl]-N-[2-(methyloxy)phenyl]acetamide |
| 09/11/2008 | US20080221180 Thiazole Derivatives and Use Thereof |
| 09/11/2008 | US20080221178 Benzimidazole Derivatives,Compositions Containing Them, Preparation Thereof and Uses Thereof |
| 09/11/2008 | US20080221173 Having dopaminergic activity comprising trigonelline and 4-hydroxyisoleucine; extracting a clear solution containing trigonelline and 4-hydroxyisoleucine from plant source; prolactin inhibitors; decrease side-effects and sexual dysfunction caused by increased Prolactin |
| 09/11/2008 | US20080221172 Use of Quaternary Pyridinium Compounds for Vasoprotection and/or Hepatoprotection |
| 09/11/2008 | US20080221169 3-carboxy aryl sulfonamide compounds, which agonize or antagonize aquaporin channels; brain trauma, head trauma, eye disorder, pulmonary disorder, lung disease, vascular disease, kidney disease, heavy metal toxicity, Alzheimer's disease, tumor, and cancer |
| 09/11/2008 | US20080221162 to treat psychosomatic disorders, respiratory, allergic conditions, inflammatory conditions, cardiac conditions, gastrointestinal conditions, conditions of the urogenital system, and conditions of the cutaneous system |
| 09/11/2008 | US20080221152 4-(heteroaryl-methyl and substituted heteroaryl-methyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists |
| 09/11/2008 | US20080221151 In which the amino is substituted by arylmethyl- or heteroarylmethyl- group, e.g., 2-Methoxybenzyl)-(2-phenylpyrrolidin-3-yl)-amine and 5-{[2-(3-Chloro-phenyl)-pyrrolidin-3-ylamino]-methyl}-6-methoxy-3-methyl-1,1a,3,7b-tetrahydro-3-aza-cyclopropa[a]naphalen-2-one; neurokinin 1 (Substance P) inhititors |
| 09/11/2008 | US20080221150 Inhibit neurodegeneration caused by lysosomal and/or mitochondrial dysfunction; bafilomycin A1, bafilomycin B1 and concanamycin |
| 09/11/2008 | US20080221147 Method of inhibiting neurotrophin-receptor binding |
| 09/11/2008 | US20080221145 Pyrroloquinoline quinone drugs for treatement of cardiac injury and methods of use thereof |
| 09/11/2008 | US20080221143 Morphine and Morphine Precursors |
| 09/11/2008 | US20080221141 1 1,1-(3-dimethylamino-3-phenylpentamethylene)-1,3,4,9-tetrahydropyrano[3,4-b]indole; affinity to mu -opioid receptor |
| 09/11/2008 | US20080221139 Novel Compounds |
| 09/11/2008 | US20080221137 Sodium channel moderators; antiarrhythmia agents; analgesics; antiarthritic agents; antiinflammatory agents; antieplipetic agents; psychological disorders; nervous system disorders |
| 09/11/2008 | US20080221136 Novel Pyrrolo [3,2-D]Pyrimidin-4-One Derivatives And Their Use In Therapy |
| 09/11/2008 | US20080221134 Parkinson's disease, catalepsy, dystonia, dyskinetic syndrome, restless legs syndrome, migraine, pain, dementia, neurodegenerative disorders, alcohol withdrawal and/or ischemic conditions such as e.g. stroke or cardiac ischemia. |
| 09/11/2008 | US20080221132 Multi-Functional Small Molecules as Anti-Proliferative Agents |
| 09/11/2008 | US20080221129 New compounds |
| 09/11/2008 | US20080221121 Controlled release of sterile freeze dried aripirazole in water for intramuscular injection |
| 09/11/2008 | US20080221114 (S)-1-(1,3-benzoxazol-2-yl)-2-[[(S)-3-methylpiperidin-1-yl]carbonyl]indoline; for treating/preventing anxiety disorder, depression, epilepsy, dementia; can selectively act on mitochondrial benzodiazepine receptor |
| 09/11/2008 | US20080221107 6-(4-chlorophenyl)-3-{4-[(3R)-3-hydroxypyrrolidin-1-yl]-3-methoxyphenyl}thieno[3,2-d][1,2,3]triazin-4(3H)-one; Melanin concentrating hormone receptor antagonist; obesity, psychiatric disorders, cognitive disorders, memory disorders, schizophrenia, epilepsy, and neurological disorders |
| 09/11/2008 | US20080221097 N-(3-Bromophenyl)-1-methyl-7-(1-piperidinylcarbonyl)-1H-imidazo[4,5-c]pyridin-4-amine hydrochloride salt; immune disorder, an inflammatory disorder, pain, rheumatoid arthritis, multiple sclerosis, osteoarthritis or osteoporosis |
| 09/11/2008 | US20080221087 Substituted lactams as inhibitors of abeta protein production |
| 09/11/2008 | US20080221086 Novel Inhibitors of Glutaminyl Cyclase |
| 09/11/2008 | US20080221081 Polymorphs of 7-[(3-chloro-6,11-dihydro-6-methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid s,s dioxide and methods of making and using the same |
| 09/11/2008 | US20080221079 Pharmaceutical composition of quetiapine fumarate |
| 09/11/2008 | US20080221078 Use of a CB1 Antagonist for Treating Side Effects and Negative Symptoms of Schizophrenia |
| 09/11/2008 | US20080221051 Gene expression inhibition; sustained release; for reduction of neuronal cell death, inflammation, and scar formation; improves wound healing, skin rejuvenation and thickening |
| 09/11/2008 | US20080221042 Amyloid precursor proteins; protein kinase C activators |
| 09/11/2008 | US20080221037 Methods and compositions for treating disorders involving excitotoxicity |
| 09/11/2008 | US20080221021 Novel Corticotropin-Releasing Factor Receptor 1 (Crfr1) Agonist |
| 09/11/2008 | US20080221013 administering a lynx1, lynx2, or lynx 3 polypeptide or nucleic acid; neurological disorder. |
| 09/11/2008 | US20080221012 Polypeptides with a functional binding domain, translocation domain, a therapeutic domain and a non-native protease cleavage site for cleavage in vitro following expression as a single chain; efficient, less dangerous production method; botulinum neurotoxins targeted to specific cell types |
| 09/11/2008 | US20080220500 Expression vector comprising nucleotide sequences coding lipogenic enzyme for treatment and prevention of cardiovascular, inflammatory, nervous system, gastrointestinal and psychological disorders |
| 09/11/2008 | US20080220092 Overcoming active agent tolerance, which may be experienced from continuous administration, improve patient compliance, and in some cases reducing the amount of drug needed per dose due to advantages of biosynchronization |
| 09/11/2008 | US20080220085 Culture of adipose stem cells; nervous system disorders |
| 09/11/2008 | US20080220084 Combination therapy for alleviating pain-related conditions |
| 09/11/2008 | US20080220079 Sustained release spherical or non-spherical pellets comprising (a) an active ingredient (b) a wax-like agent, and (c) a spheronizing agent; oral dosage forms; drug such as antivirals, vitamins, NSAIDS, antibiotics, insect growth regulators; dosing flexibility e.g. for animals |
| 09/11/2008 | US20080220062 Sustained release of agents for localized pain management |
| 09/11/2008 | US20080220057 Therapeutic compounds and methods of use |
| 09/11/2008 | US20080220020 Transdermal Botulinum Toxin Compositions |
| 09/11/2008 | US20080220013 Diagnostic Method for Brain Damage-Related Disorders |
| 09/11/2008 | US20080219984 Nucleotide sequences coding myelin-associated glycoprotein receptor for use in identifying modulators for treatment of cranial or cerebral trauma, spinal cord injury, stroke or a demyelinating disease |
| 09/11/2008 | US20080219966 Viewing attention deficit disorder as protein degradation defect and treat via trypsin, protease, chymotrypsin and/or pancreatic enzyme digestion |
| 09/11/2008 | US20080219955 Propagating nervous system tissues for use in treatment of stroke, traumatic brain injury, traumatic spinal cord injury, parkinson's, alzheimer's, huntington's, multiple sclerosis or depressive disorders; regenerative medicine; tissue engineering and repair |
| 09/11/2008 | US20080219953 Cosmid dna constructs and methods of making and using same |
| 09/11/2008 | US20080219952 culturing a human interferon producing cells in a serum-free medium, comprising hydroxyethyl piperazinyl ethanesulfonic acid(HEPES), proline sodium chloride and phenol red; drugs used for treating multiple sclerosis, viral diseases or cancer |
| 09/11/2008 | US20080219922 Alzheimer's Disease Imaging Agents |
| 09/10/2008 | EP1967527A1 A g protein-coupled receptor antagonist and its use for preventing and treating alzheimer s disease |
| 09/10/2008 | EP1967525A2 A method for regulating immune function in primates using the foxp3 protein |
| 09/10/2008 | EP1967523A1 New thiophen glycoside derivatives, method for their manufacture, medicines containing these compounds and their application |
| 09/10/2008 | EP1967519A1 3,4-dihydrobenzoxazine compound and inhibitor of vanilloid receptor type 1 (vr1) activity |
| 09/10/2008 | EP1967517A1 Probe for diagnosis of conformational disease |
| 09/10/2008 | EP1967210A1 Novel application of apelin |
| 09/10/2008 | EP1967195A1 Antacid |
| 09/10/2008 | EP1967192A1 N-amidino pyrazinecarboxamide derivatives for use in the prophylaxis or treatment of neurodegenerative diseases |